← Eichor
Condition: Egfr Del19 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Egfr Del19

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Phase 1/Phase 2 · 1 location(s) · Wayshine Biopharm, Inc. · NCT07206498A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Pat
Phase 1 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT06955988A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant
NA · 36 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06053099
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.